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to use olanzapine but reenforce recommendation for risperidone. Olanzapine's affinity to 5-HT2A receptors is 2 nM compared with 0.17 nM for risperidone. This difference is significant. The lower affinity predicts poor efficacy against JCV. In reviewing the psychiatric literature on affinity data of 5-HT2A, (and every other neurotransmitter) it is important to remember the profound difference between receptor occupancy at a given dose and affinity. They can be, but are not necessarily related. Receptor occupancy at or close to 100% is presumably required, 3 but not sufficient for exertion of a JCV antiviral effect. If drug affinity is lower than that of JCV -a value currently unknown -then JCV would displace drugs even when the drug otherwise has 100% receptor occupancy at a given dose. This expectation is similar to how a drug with higher receptor affinity will displace a drug with lower affinity even though the lower-affinity drug previously had 100% receptor occupancy. Of many clinical examples where this occurs, the higher-affinity naloxone's displacement of the loweraffinity morphine at mu opioid receptors is perhaps best known.
Ziprasidone at 20 mg p.o. (twice daily) would be expected to give inadequate receptor occupancy. Previous work suggests 40% at 12 h after this dose. 5 Until research can tell us a better approach, we recommend risperidone at 4 mg p.o. twice daily for PML patients, with pharmacological conversion of extensive metabolizers at CYP 2D6 to poor metabolizers because extensive metabolizers at 2D6 show somewhat diminished 5-HT2A receptor occupancy by risperidone compared to poor metabolizers, 6, 7 corresponding to greater amounts of risperidone, less 9-hydroxyrisperidone in poor metabolizers (Table 2 ). Conversion can be done rather easily and safely by concomitant use of potent CYP 2D6 inhibitors like the antidepressant paroxetine. Tobacco, phenobarbital and rifampicin have potential to upregulate 2D6 protein and so must be avoided during treatment of PML with risperidone.
Urine studies on normals and psychiatric patients starting treatment with drugs of Table 1 should also be T max is time from intake to peak blood levels. T 1/2 is time for blood level to decrease by 50%. 9-Hydroxy risperidone is the main catabolite of risperidone and shares much, but not all, the 5-HT2A binding affinity of the parent compound. Extensive metabolizers of debrisoquine (by CYP 2D6) are the majority of the population in Europe and they have considerably more of the lower affinity metabolite 9-hydroxyrisperidone than do poor metabolizers (see Table 2 ). Affinity data taken from references as listed in http://pdsp.cwru.edu/pdsp.php, the website of the NIMH Psychoactive Drug Screening Program. Commonly accepted ratio of poor to extensive metabolizers in European Caucasian populations and the effects of this status on risperidone metabolism. 6, 7 Ratios may be quite different in other populations.
carried out. Forty percent of a healthy adult population without signs or symptoms of urinary tract or any other disease or problem will shed several million JCV copies per ml urine. 8 The drug regimen most effective at eliminating this in urine might predict the best regimen in treating PML. All the suggested drugs in Table 1 readily cross the blood-brain barrier.
Summary of our current considerations and recommendations for further study:
1. Amoxapine is an older antidepressant with some atypical antipsychotic activity. At 100 mg twice daily, amoxapine is cheap and often well tolerated, but we have less affinity data than we do on the other two drugs. The data that does exist show somewhat lower affinity than risperidone and ziprasidone. High affinity would have to be confirmed before human trials. 2. Ziprasidone at 160 mg twice daily is perhaps less well tolerated in conscious patients than high-dose (4 mg twice daily) risperidone but any dose lower than this would not be expected to occupy enough receptors to block JCV replication. 3. Risperidone at 4 mg twice daily, with all patients being converted to poor metabolizers with paroxetine, 40 mg twice daily is our current favored approach. Risperidone is the one treatment that seems to have worked in a single reported patient 2 and will be our approach until research can guide us to a better one. 
